Quanterix’ digital biomarker detection technology, Simoa, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low - even baseline - levels, in most common sample types.
Detecting the Undetectable
Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.
First of its kind detection capabilities
This innovative technology is perfectly suited for single- and multi-plex detection of key biomarkers at ultra-low levels in applications within all therapeutic areas, including oncology, neurology, cardiology, immunology, and infectious disease.
Detect biomarkers at femtogram levels
The innovative digital nature of the technique allows an average of 1000 times sensitivity increase over conventional assays, with CVs less than 10 percent.
See results in record time
Incubation time for analyte capture and detector binding is typically about 30 minutes, with five minutes for labeling by the streptavidin β-galactosidase (SBG) conjugate.
The evolution of the immunoassay
Revolutionizing new discoveries with ultra-sensitive detection
SIMOA Bead and Planar Technology
Enable detection of thousands more targets for drug development, efficacy, and safety.
How it works
A high level look at a Simoa Bead-based assay, from development to data analysis.
Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
Detection antibodies – capable of generating fluorescent product – are added.
The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
At low concentrations, each bead will contain one bound protein, or none.
The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.